Primer: Chongqing Zhifei Biological Products (300122 CH) - Aug 2026
Chongqing Zhifei's financial performance has deteriorated significantly, posting its first annual net loss since listing in 2025, driven by a...
99 Views
Quam Morning Note (21 Aug)
The HSI closed at 25,698, up 203 pts or 0.8%, as gains in healthcare and technology stocks lifted the market. Healthcare and biotechnology stocks...
97 Views
CSI 300 Index Earning Revision (Sep): CHINA VANKE, CHINA RAILWAY CONSTRUCTION, COSCO SHIPPING
We analyzed CSI 300's consensus for Sep 2026 and highlighted changes of EPS in CHINA VANKE (000002 CH), CHINA RAILWAY CONSTRUCTION (601186 CH),...
93 Views
APAC Healthcare Weekly (April 20)- Neuren, Chugai, Eisai, Telix, Biocon, Aurobindo Pharma
Neuren is a step closer to P3 trial in PMS. Chugai’s oral GLP-1 drug candidate shows promise in P3 trial. Eisai got Leqembi approval in EU. Biocon...
806 Views
APAC Healthcare Weekly (Dec 8)- Eoflow, Celltrion, Takeda, Medipal, SanBio, Aurobindo Pharma
The insight covers key developments in prominent APAC healthcare companies. These developments are expected to impact the financials of the...
654 Views